SEBASTIEN SANGES

Dr. SEBASTIEN SANGES

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2017 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
AAAlexandra Audemard‐Verger
Alexandra Audemard‐Verger
BTBenjamin Terrier
Benjamin Terrier
ADAgnès Dechartres
Agnès Dechartres
JCJohan Chanal
Johan Chanal
ZAZahir Amoura
Zahir Amoura
OGon behalf of the French Vasculitis Study Group
on behalf of the French Vasculitis Study Group

1 September 2016 in Medicine
Verified
Journal Article
Open access
SSSEBASTIEN SANGES
SEBASTIEN SANGES
CYCécile M. Yelnik
Cécile M. Yelnik
OSOlivier Sitbon
Olivier Sitbon
OBOlivier Benveniste
Olivier Benveniste
KMKuberaka Mariampillai
Kuberaka Mariampillai
EHEric Hachulla
Eric Hachulla
Occurrence of pulmonary arterial hypertension (PAH) in idiopathic inflammatory myopathies (IIMs) without extensive interstitial lung disease (ILD) has rarely been described in the medical literature. This study aimed to report all cases with association of PAH and IIM in the French Pulmonary Hypertension (PH) Registry, to identify IIM features associated with the presence of PAH, and to describe treatment modalities of these patients.All cases of IIM-PAH were retrieved from the French PH Registry, which gathers PH patients prospectively enrolled by 27 referral hospital centers across France. Patients were excluded if they had an extensive ILD or overlap syndrome. Characteristics of IIM-PAH patients were compared with a control group of IIM patients without PH.Among the 5223 PH patients in the Registry, 34 had a diagnosis of IIM. Among them, 3 IIM-PAH patients (2 females and 1 male) had no evidence of extensive ILD or overlap syndrome, and were included in this study. In these 3 patients, dermatomyositis (DM) was the only identified IIM. One patient had autoantibodies classically associated with IIM (anti-Ku). PAH had always developed after IIM onset, was severe in all cases, and led to a marked functional impairment.By pooling our cases with 6 patients previously reported in the literature, and comparing them with a control cohort of 35 IIM patients without PH, we identify several IIM characteristics possibly associated with PAH occurrence, including DM subtype (78% vs 46%; P = 0.02), skin involvement (P = 0.04), anti-SSA antibodies (P = 0.05), and peripheral microangiopathy (P = 0.06).Overall, IIM-PAH patients were managed by corticosteroids and/or immunosuppressants, either alone or combined with PAH therapy. Patients did not seem to respond to IIM treatment alone.Our study reports for the first time the rare but possible association of PAH and IIM in a large prospective PH Registry. In that setting, PAH seems associated with DM, skin involvement, peripheral microangiopathy, and anti-SSA positivity. The best therapeutic strategy for IIM-PAH remains to be defined.

1 April 2017 in Autoimmunity Reviews
Verified
Journal Article
Closed access
SSSEBASTIEN SANGES
SEBASTIEN SANGES
SRSébastien Rivière
Sébastien Rivière
AMArsène Mekinian
Arsène Mekinian
TMThierry Martin
Thierry Martin
AQAlain Le Quellec
Alain Le Quellec
DLDavid Launay
David Launay

1 February 2017 in La Revue de Médecine Interne
Verified
Journal Article
Closed access
SSSEBASTIEN SANGES
SEBASTIEN SANGES
TGT. Guerrier
T. Guerrier
DLDavid Launay
David Launay
GLG. Lefèvre
G. Lefèvre
MLM. Labalette
M. Labalette
SDS. Dubucquoi
S. Dubucquoi

5 December 2022 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
SSSEBASTIEN SANGES
SEBASTIEN SANGES
LRLisa Rice
Lisa Rice
LTLy Tu
Ly Tu
EVEleanor Valenzi
Eleanor Valenzi
JCJean-Luc Cracowski
Jean-Luc Cracowski
RLRobert Lafyatis
Robert Lafyatis
Objectives To mine the serum proteome of patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) and to detect biomarkers that may assist in earlier and more effective diagnosis and treatment. Methods Patients with limited cutaneous SSc, no extensive interstitial lung disease and no PAH-specific therapy were included. They were classified as cases if they had PAH confirmed by right heart catheterisation (RHC) and serum collected on the same day as RHC; and as controls if they had no clinical evidence of PAH. Results Patients were mostly middle-aged females with anticentromere-associated SSc. Among 1129 proteins assessed by a high-throughput proteomic assay (SOMAscan), only 2 were differentially expressed and correlated significantly with pulmonary vascular resistance (PVR) in SSc-PAH patients (n=15): chemerin (ρ=0.62, p=0.01) and SET (ρ=0.62, p=0.01). To validate these results, serum levels of chemerin were measured by ELISA in an independent cohort. Chemerin levels were confirmed to be significantly higher (p=0.01) and correlate with PVR (ρ=0.42, p=0.04) in SSc-PAH patients (n=24). Chemerin mRNA expression was detected in fibroblasts, pulmonary artery smooth muscle cells (PA-SMCs)/pericytes and mesothelial cells in SSc-PAH lungs by single-cell RNA-sequencing. Confocal immunofluorescence revealed increased expression of a chemerin receptor, CMKLR1, on SSc-PAH PA-SMCs. SSc-PAH serum seemed to induce higher PA-SMC proliferation than serum from SSc patients without PAH. This difference appeared neutralised when adding the CMKLR1 inhibitor α-NETA. Conclusion Chemerin seems an interesting surrogate biomarker for PVR in SSc-PAH. Increased chemerin serum levels and CMKLR1 expression by PA-SMCs may contribute to SSc-PAH pathogenesis by inducing PA-SMC proliferation.

1 September 2014 in Autoimmunity Reviews
Verified
Journal Article
Closed access
ALAurélia Lanteri
Aurélia Lanteri
VSVincent Sobanski
Vincent Sobanski
CLCarole Langlois
Carole Langlois
GLGuillaume Lefèvre
Guillaume Lefèvre
CHCarine Hauspie
Carine Hauspie
SDSylvain Dubucquoi
Sylvain Dubucquoi